ArticleAntimicrobial resistance and infection control2019

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).

Thitima Kongnakorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.